CM Life Sciences III closed its IPO of 55.2 million units at $10 each, including 7.2 million units issued pursuant to the exercise in full by the underwriters’ over-allotment option.
Units trade on the Nasdaq under CMLTU. Each consists of one share of Class A common stock and one-fifth of one redeemable warrant, with each whole warrant exercisable at $11.50. After the securities comprising the units begin separate trading, shares and warrants are expected to list under CMLT and CMLTW, respectively.
This is the latest SPAC launched by CEO Eli Casdin, founder of Casdin Capital, an investment firm focused on the life sciences and healthcare industry. Read more.
